- We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6. This asset was in-licensed from Novimmune in January 2017.
- IL-6r mAb has a novel mechanism of action, binding to both the membrane-bound and soluble forms of the IL-6r, blocking the IL-6/IL-6r complex as well as depleting circulating levels of IL-6 in the blood.
- Excessive production of IL-6 is regarded as a key driver of chronic inflammation, associated with autoimmune diseases such as multiple myeloma, oncology indications and rheumatoid arthritis. We believe that TZLS-501 may have the potential therapeutic value to fight these indications.
- In preclinical studies, TZLS-501 demonstrated that its novel mechanism of action has the potential to overcome the limitations of other IL-6 blocking pathway drugs.